See more : Youngevity International, Inc. (YGYI) Income Statement Analysis – Financial Results
Complete financial analysis of Elixinol Wellness Limited (ELLXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elixinol Wellness Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Dufry AG (DUFRY) Income Statement Analysis – Financial Results
- CytoTools AG (T5O.DE) Income Statement Analysis – Financial Results
- Guangzhou Pearl River Piano Group Co.,Ltd (002678.SZ) Income Statement Analysis – Financial Results
- CTEEP – Companhia de Transmissão de Energia Elétrica Paulista S.A. (TRPL4.SA) Income Statement Analysis – Financial Results
- Reliance Global Group, Inc. (RELI) Income Statement Analysis – Financial Results
Elixinol Wellness Limited (ELLXF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.elixinolwellness.com
About Elixinol Wellness Limited
Elixinol Wellness Limited, through its subsidiaries, manufactures and distributes hemp derived nutraceuticals, cosmetics, and food products under the Elixinol and Hemp Foods Australia brands in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.27M | 7.06M | 9.34M | 15.01M | 27.18M | 37.13M | 0.00 |
| Cost of Revenue | 4.85M | 3.82M | 4.44M | 8.34M | 11.56M | 17.18M | 17.00K |
| Gross Profit | 3.42M | 3.24M | 4.90M | 6.67M | 15.62M | 19.96M | -17.00K |
| Gross Profit Ratio | 41.36% | 45.90% | 52.43% | 44.41% | 57.46% | 53.74% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.17M | 8.08M | 12.95M | 17.54M | 19.73M | 10.76M | 6.35M |
| Selling & Marketing | 1.82M | 2.29M | 3.68M | 7.17M | 12.25M | 7.41M | 36.00K |
| SG&A | 7.99M | 10.37M | 16.64M | 24.71M | 31.98M | 18.18M | 2.72M |
| Other Expenses | -4.57M | 472.00K | 2.51M | 522.00K | 88.00K | 734.00K | 0.00 |
| Operating Expenses | 3.42M | 13.24M | 20.51M | 31.99M | 39.38M | 20.93M | 2.72M |
| Cost & Expenses | 14.26M | 17.06M | 24.95M | 40.34M | 50.95M | 38.11M | 2.74M |
| Interest Income | 213.00K | 22.00K | 47.00K | 100.00K | 559.00K | 441.00K | 6.00K |
| Interest Expense | 101.00K | 71.00K | 92.00K | 49.00K | 121.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 597.00K | 721.00K | 1.49M | 3.21M | 2.80M | 612.00K | 17.00K |
| EBITDA | -6.84M | -9.28M | -14.12M | -22.11M | -22.29M | -150.00K | -8.15M |
| EBITDA Ratio | -82.71% | -117.52% | -109.00% | 348.66% | -82.00% | -0.40% | 0.00% |
| Operating Income | -5.99M | -9.01M | -11.67M | 49.12M | -24.74M | -974.00K | -2.74M |
| Operating Income Ratio | -72.44% | -127.74% | -124.95% | 327.26% | -91.02% | -2.62% | 0.00% |
| Total Other Income/Expenses | -1.51M | -1.04M | -193.00K | -78.16M | -49.85M | 477.00K | -5.46M |
| Income Before Tax | -7.50M | -10.57M | -17.09M | -100.28M | -73.62M | -497.00K | -2.73M |
| Income Before Tax Ratio | -90.75% | -149.81% | -183.02% | -668.07% | -270.82% | -1.34% | 0.00% |
| Income Tax Expense | 3.00K | 2.00K | -65.00K | 4.20M | -7.20M | 363.00K | -22.00K |
| Net Income | -7.51M | -10.57M | -17.03M | -104.51M | -83.34M | -860.00K | -2.71M |
| Net Income Ratio | -90.78% | -149.84% | -182.32% | -696.24% | -306.60% | -2.32% | 0.00% |
| EPS | -0.02 | -0.03 | -0.04 | -0.45 | -0.42 | -0.01 | -0.03 |
| EPS Diluted | -0.02 | -0.03 | -0.04 | -0.45 | -0.42 | -0.01 | -0.03 |
| Weighted Avg Shares Out | 472.14M | 406.38M | 404.77M | 230.68M | 196.99M | 125.36M | 103.09M |
| Weighted Avg Shares Out (Dil) | 473.42M | 406.38M | 404.77M | 230.68M | 196.99M | 125.36M | 102.93M |
Study on the safety of Elixinol Hemp Extract is published in Journal of Toxicology
SYDNEY , Feb. 2, 2024 /PRNewswire/ -- Elixinol Wellness Limited (ASX: EXL) continues to be a pioneer in the global hemp industry, with the release of a new paper into the safety of Elixinol Hemp Extract in leading scientific publication,...
Elixinol Wellness strikes deal with British Cannabis to continue distribution in the UK
Elixinol Wellness Ltd (ASX:EXL, OTCQB:ELLXF) has entered into a three-year exclusive licensing agreement with CBD Health Foods Ltd, trading as British Cannabis, to manufacture, market and sell CBD products across the UK. The agreement follows the company's recent decision to...
Elixinol Wellness well-funded over next 18 months to take advantage of improving outlook across key markets
Elixinol Wellness Ltd has more than 18 months of funding in hand to take advantage of an improving outlook in the US and Australia. With a steadily reducing cost base and with more optimisation initiatives on foot, the leading player in...
Elixinol Wellness delivers best EBITDA and earnings since first half 2019
Elixinol Wellness Ltd (ASX:EXL, OTCQB:ELLXF, FRA:E8M) has tabled its interim financial results for the 2021 financial year, recording a 53% improvement in adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) on the previous corresponding period (PCP). The hemp-focused ASX-lister...
Elixinol Wellness returns to growth in June quarter as it seeks to expand existing markets and new growth drivers
Elixinol Wellness Ltd has returned to revenue growth, finishing the quarter with the best revenue recorded in June since October 2020, led by its Hemp Foods Australia business, up 19% from the previous quarter. The company ended the June quarter...
Elixinol Wellness and CannaCare Health terminate acquisition as changing German market dynamics threaten returns
Elixinol Wellness Ltd (ASX:EXL) (OTCQB:ELLXF) (FRA:E8M) and German-based CBD business CannaCare Health GmbH have mutually agreed to terminate a share purchase agreement following a changing German cannabis market that revealed financial concerns. Elixinol will be reimbursed €360,000 by CannaCare to...
Elixinol Wellness in trading halt with an announcement related to proposed acquisition pending
Elixinol Wellness Ltd (ASX:EXL) (OTCMKTS:ELLXF) has been granted a trading halt pending an announcement regarding the proposed acquisition of CannaCare Health GmbH. The halt will remain in place until the start of regular trading on Wednesday, June 30, or until an announcement...
Elixinol Wellness and Health House International unite with medicinal cannabis distribution agreement
Elixinol Wellness Ltd (ASX:EXL) (OTCMKTS:ELLXF) is poised to enhance its service of the Australian CBD market under a new partnership with pharmaceutical distributor Health House International Ltd (ASX:HHI). From July, Health House's Australian offshoot will distribute Elixinol's hemp-derived CBD products in Australia...
Elixinol Wellness Makes Key Appointments To Leadership Team
SYDNEY, May 18, 2021 /PRNewswire/ -- Elixinol Wellness Limited (Elixinol Wellness or the Company) (ASX:EXL; OTCQB:ELLXF), a global leader in the hemp derived CBD industry, innovating, and selling hemp derived CBD products, is pleased to announce the appointment of Rob...
Elixinol Global sees steady improvements in first quarter revenue as UK COVID restrictions ease and US stimulus packages take effect
Elixinol Global Ltd's (ASX:EXL) (OTCMKTS:ELLXF) (FRA:E8M) group revenue steadily improved across the course of the March quarter as consumers recovered from Christmas trading periods, COVID-related restrictions started to ease in the UK and the impact of US stimulus packages took effect. Its...
Source: https://incomestatements.info
Category: Stock Reports